FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Leerink Partnrs cut their FY2024 EPS estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($3.04) for the year, down from their previous forecast of ($2.65). The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' Q4 2024 earnings at ($0.73) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.55) EPS and FY2027 earnings at ($2.51) EPS.

A number of other analysts have also weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Wednesday, November 13th. Chardan Capital boosted their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright raised their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Lexeo Therapeutics has an average rating of "Buy" and an average target price of $22.71.

Lexeo Therapeutics Trading Down 9.8 %

Shares of LXEO traded down $0.65 during mid-day trading on Monday, reaching $6.00. 503,828 shares of the company's stock traded hands, compared to its average volume of 251,480. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. The stock's 50-day moving average is $9.01 and its two-hundred day moving average is $12.23. Lexeo Therapeutics has a 12 month low of $5.81 and a 12 month high of $22.33. The stock has a market cap of $198.40 million and a P/E ratio of -1.93.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the firm's stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company's stock, valued at approximately $977,629.50. This trade represents a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 12,500 shares of company stock worth $113,300. 4.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LXEO. Frazier Life Sciences Management L.P. purchased a new stake in Lexeo Therapeutics in the third quarter valued at $11,307,000. RA Capital Management L.P. acquired a new position in shares of Lexeo Therapeutics in the 1st quarter valued at about $10,364,000. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company's stock worth $33,997,000 after acquiring an additional 599,203 shares during the period. Point72 Asset Management L.P. acquired a new position in Lexeo Therapeutics in the third quarter valued at approximately $3,348,000. Finally, Verition Fund Management LLC grew its stake in shares of Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company's stock worth $7,027,000 after purchasing an additional 355,928 shares during the period. Institutional investors and hedge funds own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.